Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + ramucirumab with pegylated G-CSF support in elderly advanced NSCLC
jRCTs051180232Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, ramucirumab and pegfilgrastim in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Response rate. Started Mar 2018; status: completed.
02
Drugs
docetaxelramucirumabpegfilgrastim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051180232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180232.